Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Tomivosertib Versus Acute Myeloid Leukemia

Oncotarget

May 12, 2021
In the cover paper chosen for Oncotarget’s Volume 12, Issue 10, researchers investigated the efficacy of Tomivosertib in pre-clinical models of acute myeloid leukemia (AML). continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #10

Oncotarget

May 12, 2021
Read the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 10. continue reading »

Behind the Study: Extending Survival in Glioma Models

Oncotarget

May 11, 2021
Dr. Gregory Riggins from Johns Hopkins University discusses his 2017 study published by Oncotarget, entitled, "Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients." continue reading »

Trending With Impact: Composite Score May Further Classify HCC

Oncotarget

May 7, 2021
In this trending study, the association between IGF/CTP composite scores, overall survival, and progression-free survival of hepatocellular carcinoma patients treated with sorafenib was investigated. continue reading »

New Analogs of Mibefradil Created as Radiosensitizers for Glioblastoma

Oncotarget

May 5, 2021
Researchers from Yale University conducted a study to create mibefradil analogs as superior radiosensitizers in glioblastoma treatments. continue reading »